Valeritas (NSDQ:VLRX) today announced the results of a study that showed patients using its V-Go wearable insulin delivery device needed less insulin, had lower A1c levels and reduced diabetes-related medication cost compared with patients using multiple daily injection (MDI) therapy.
The retrospective study by the Bridgewater, N.J.-based company used information from the HealthCore Integrated Research Database (HIRD).
Get the full story on our sister site, Drug Delivery Business.